Zacks Investment Research on MSN1h
Will Auvelity & Other Drugs Aid AXSM's Growth Amid Stiff Competition?Axsome Therapeutics’ AXSM Auvelity (AXS-05) was launched in the United States in 2022 for the treatment of major depressive disorder (MDD), making it the first approved drug in the company’s portfolio ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback